{"id":324,"date":"2021-02-16T10:06:47","date_gmt":"2021-02-16T08:06:47","guid":{"rendered":"https:\/\/bcamonitor.org\/?p=324"},"modified":"2026-09-22T13:34:54","modified_gmt":"2026-09-22T13:34:54","slug":"what-is-the-place-of-urinary-markers-in-nmibc-follow-up","status":"publish","type":"post","link":"https:\/\/bcamonitor.org\/?p=324","title":{"rendered":"What is the place of urinary markers in NMIBC follow-up?"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;0px|||||&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; min_height=&#8221;446px&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; header_text_color=&#8221;#3b8dbf&#8221; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;]<\/p>\n<h1 class=\"entry-title\">Watch the webinar by Prof. Fred Witjes<\/h1>\n<p>On Thursday 21 January 2021, MML-Medical, partner of Nucleix in the Netherlands, organised the webinar \u201c<strong>Follow-up of NMIBC, including the place of urinary markers<\/strong>\u201d. The webinar included 45 minutes lecture by Prof. Dr. Fred Witjes, Professor of oncological urology, and 15 minutes Q&amp;A, chaired by Dr. Toine van der Heijden, oncological urologist, both from the Radboud UMC Nijmegen, the Netherlands.<\/p>\n<p>Watch this webinar to learn more about:<\/p>\n<ul>\n<li>The current guidelines on treatment and follow-up of Non Muscle-Invasive Bladder Cancer (NMIBC)<\/li>\n<li>The pitfalls of the current follow-up procedures<\/li>\n<li>Urinary markers in follow-up of NMIBC and promising results from clinical studies<\/li>\n<li>Practical considerations about using biomarker tests in clinical practice<\/li>\n<\/ul>\n<p>[\/et_pb_text][et_pb_video src=&#8221;https:\/\/youtu.be\/IImwfPx1mA8&#8243; thumbnail_overlay_color=&#8221;rgba(0,0,0,0.6)&#8221; _builder_version=&#8221;4.16&#8243; width=&#8221;70%&#8221; module_alignment=&#8221;center&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][\/et_pb_video][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_button button_url=&#8221;https:\/\/bcamonitor.org\/slides-brochure\/&#8221; button_text=&#8221;Download the free slide resource and brochure&#8221; button_alignment=&#8221;center&#8221; _builder_version=&#8221;4.16&#8243; custom_button=&#8221;on&#8221; button_text_color=&#8221;#ffffff&#8221; button_bg_color=&#8221;#3b8dbf&#8221; button_border_width=&#8221;0px&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.8.2&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;2px||5px|||&#8221; global_module=&#8221;303&#8243; saved_tabs=&#8221;all&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Watch the webinar by Prof. Fred Witjes On Thursday 21 January 2021, MML-Medical, partner of Nucleix in the Netherlands, organised the webinar \u201cFollow-up of NMIBC, including the place of urinary markers\u201d. The webinar included 45 minutes lecture by Prof. Dr. Fred Witjes, Professor of oncological urology, and 15 minutes Q&amp;A, chaired by Dr. Toine van [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":175,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[7],"tags":[],"class_list":["post-324","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-webinar"],"_links":{"self":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=324"}],"version-history":[{"count":1,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/324\/revisions"}],"predecessor-version":[{"id":387,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/324\/revisions\/387"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/media\/175"}],"wp:attachment":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}